Nasdaq GlobeNewswire

Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio

Del

--  Facility to support development of advanced gene and cell therapies for treatment of life-threatening rare diseases

  --  Leaders from local government, life sciences and medical technology to join on October 4 for dedication of first anticipated gene and cell therapy production center in Ohio

CLEVELAND, Oct. 04, 2017 (GLOBE NEWSWIRE) --  Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today the ground-breaking of the first anticipated commercial gene therapy manufacturing facility in Ohio. The Cleveland-based facility, named The Elisa Linton Center for Rare Disease Therapies, will have the capacity to produce advanced gene and cell therapies to treat serious and debilitating rare diseases. The dedication and ground-breaking ceremony is being held today, October 4, 2017.  

"We are very excited to announce the creation of The Elisa Linton Center for Rare Disease Therapies, which will be a global resource for production of gene therapies with the potential to bring new treatments to rare disease patients around the world," said Timothy J. Miller, Ph.D., President and CEO of Abeona Therapeutics. "It is especially fitting that this center is named for Elisa Linton, who was born with Sanfilippo syndrome, a rare terminal disease. The memory of Elisa and courage of her family continue to be a great inspiration to all members of the rare disease community."

The Elisa Linton Center for Rare Disease Therapies will initially be used to produce ABO-101 and ABO-102, investigational gene therapies currently in development at Abeona for the treatment of patients with Sanfilippo syndrome, and EB-101, an investigational autologous cell therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare and devastating skin disorder. The Center will also house Abeona's expanded viral-vector lab, which will develop and produce unique and proprietary vectors used for the delivery of gene therapies. The 6,000 square foot Center will be built-out and validated over the next 12 months.

"The Epidermolysis Bullosa Medical Research Foundation, along with the EB Research Partnership, is a longtime supporter of research that may help patients living with EB including the development of EB-101. The development of EB-101 is a great example of the progress we are making in EB research today," said Paul Joseph, Chief Financial Officer of the Epidermolysis Bullosa Medical Research Foundation. "We are very pleased to support Abeona taking steps to establish a world-class gene therapy production facility that will bring new hope to people living with EB and other serious diseases and conditions."

Several leaders from local government and life sciences are scheduled to attend the dedication ceremony of the Center, including representatives from United States Senator Sherrod Brown's office, Case Western Reserve University, BioEnterprise, MidTown Cleveland, Inc. and JumpStart Inc.

"Today's groundbreaking celebration represents another successful investment in Ohio innovation and manufacturing," said Senator Brown. "It's exciting to see investments in gene therapy treatments for rare diseases happening right here in Cleveland, helping to cement Ohio's leadership in the healthcare and technology industries. Today's ceremony is another step forward for the health of rare disease patients and for the strength of the region's economy."

"We applaud Abeona's decision to open a state-of-the-art gene therapy facility in Cleveland's Health-Tech Corridor," said Aram Nerpouni, President and CEO of BioEnterprise. "The Cleveland bioscience industry has grown remarkably in the past decade and Abeona's investment is a potent example of our region's momentum. We look forward to our ongoing relationship with Abeona and other emerging bioscience companies that continue to grow and strengthen our local economy."

About EB Medical Research Foundation: As the leader in research funding, the Epidermolysis Bullosa Medical Research Foundation is an all-volunteer, non-profit 501(c) Foundation dedicated to funding research for Epidermolysis Bullosa to determine its causes, develop successful treatments, and ultimately find a cure. EB is a rare, debilitating and often fatal genetic disorder which causes painful scarring and blistering of the skin and internal organs. Our continued goal is to raise awareness through special events, the media and fundraising programs. www.ebmrf.org

About BioEnterprise: BioEnterprise is a business formation, recruitment, and acceleration effort designed to support the growth of bioscience companies. Located in Cleveland, BioEnterprise provides management counsel and support services to health IT, medical device, and biopharmaceutical companies. BioEnterprise founders are Case Western Reserve University, Cleveland Clinic, and University Hospitals. Additional technology partners include the NASA Glenn Research Center, Cleveland State University, and BioOhio. The initiative comprises the collective activities of BioEnterprise and its partners' commercialization offices: The Case Office of Technology Transfer, Cleveland Clinic Innovations, and University Hospitals Cleveland - Center for Clinical Research. The combined efforts of these groups has created, recruited, and accelerated more than 300 companies in 15 years. For more information: www.BioEnterprise.com.

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).  Abeona is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a proprietary vector platform, AIM(TM), for next generation product candidates.  For more information, visit www.abeonatherapeutics.com.

Investor Contact:
Christine Silverstein
Vice President, Investor Relations
Abeona Therapeutics Inc.
+1 (212) 786-6212
csilverstein@abeonatherapeutics.com

Media Contact: 
Lynn Granito
Berry & Company Public Relations  
+1 (212) 253-8881  
lgranito@berrypr.com

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, that patients will continue to be identified, enrolled, treated and monitored in the EB-101 clinical trial, and that studies will continue to indicate that EB-101 is well-tolerated and may offer significant improvements in wound healing; the addition of two additional global clinical sites will accelerate our ability to enroll and evaluate ABO-102 as a potential treatment for patients with Sanfilippo syndrome type A, or MPS IIIA.  Such statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to secure licenses for any technology that may be necessary to commercialize our products; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; our belief that initial signals of biopotency and clinical activity, which suggest that ABO-102 successfully reached target tissues throughout the body, including the central nervous system and the increased reductions in CNS GAG support our approach for intravenous delivery for subjects with Sanfilippo syndromes, and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and quarterly reports on Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abeona Therapeutics Inc via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Clinical data demonstrates significantly increased cure rates using Resistance Guided Therapy for treating the STI Superbug M. genitalium21.6.2018 09:00Pressemelding

SpeeDx ResistancePlus® MG test supports new STI management guidelines SYDNEY, Australia, June 21, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. today announced clinical data contained in a new study published in the June 2018 issue of Clinical Infectious Diseases 1 [link ] supports the use of Resistance Guided Therapy for more effective treatment of Mycoplasma genitalium infections. Using the SpeeDx ResistancePlus® MG test, the authors recorded an overall cure rate of >92%, a significant increase compared with previous cure rates of 67% prior to using Resistance Guided Therapy.ResistancePlus MG test simultaneously detects the sexually transmitted infection (STI) M. genitalium and the genetic markers linked to antimicrobial resistance (AMR). The test is CE marked and in use across Europe, and available in laboratories across Australia and New Zealand. Clinical trials are underway in the U.S. in preparation for de novo clearance for the test with the U.S. Food and Drug Administration. "This

LM Industries Brings Manufacturing Into the Future as World's First Digital OEM20.6.2018 18:00Pressemelding

The creators of autonomous shuttle Olli form LM Industries, a company designing and building future-looking products with partners like Allianz, Airbus and the United States Marine Corps SAN FRANCISCO, June 20, 2018 (GLOBE NEWSWIRE) -- Today, the creators of the Rally Fighter and Olli announced the formation of LM Industries Group, Inc., a technology-enabled manufacturer focused on mobility products headquartered in San Francisco. LM Industries is the world's first digital OEM - which can take concepts to deployed products in under one year, all on its unique digital thread. It brings products to market in an entirely new way, designing with its global community of experts, and applying technology such as 3D printing to create and assemble products in small batches at agile microfactories. The process challenges the century-long dependency on mass manufacturing which has failed to keep up with the modern pace of technological innovation. LM Industries creates transportation, accessibil

Anglo American, Milliken & Company, MOL Group, Koch Industries, Goldcorp and AccorHotels among the Excellence Award winners at Enablon's Sustainable Performance Forum20.6.2018 17:15Pressemelding

Enablon recognizes companies for effectively leveraging technology to improve their sustainability performance CHICAGO, June 20, 2018 (GLOBE NEWSWIRE) -- Enablon, a Wolters Kluwer business and the world's leading provider of EHS, Operational Risk Management and Sustainability Software, announced today the winners of the 2018 Enablon Excellence Awards. The awards were given during a gala dinner at the Sustainable Performance Forum (SPF) in Chicago, and in Paris. The Enablon Excellence Awards recognize organizations that are leading the way within their industry and that effectively leverage technology to improve their sustainability performance to benefit their business, and also their employees, customers and the communities in which they operate. The 2018 Excellence Awards winners are: Enablon Excellence Award in EHS Performance: Koch Industries (Americas) & MOL Group (EMEA) Enablon Excellence Award in Governance, Risk & Compliance (EMEA): AccorHotels Enablon Excellence Award in Integ

Datameer Named Leader in Ovum Self-Service Data Prep Decision Matrix20.6.2018 15:40Pressemelding

Datameer ranked among top vendors for integration and exploration, data manipulation, data governance, and administration SAN FRANCISCO, June 20, 2018 (GLOBE NEWSWIRE) -- Datameer, the leader in big data management for analytics, is pleased to announce that it was named a leader in the Ovum Decision Matrix, Selecting a Self-Service Data Prep Solution, 2018-2019, ahead of Alteryx, Datawatch and Oracle. The report highlights Datameer as "a broad and complex platform [..] focused on building and managing data pipelines that enable data to be fed into any analytic tool." "In the self-service data prep market, we're increasingly seeing the trend of 'platformization' of products, whereby data prep becomes a feature rather than a stand-alone tool," said report author Paige Bartley, senior analyst at Ovum. "Datameer has taken this approach, offering a broad platform focused on data pipelines and self-service enablement. But with a broader platform and functionality comes the need for greater g

Kofax Robotic Process Automation Software Creates Smarter Robots20.6.2018 14:00Pressemelding

Kapow 10.3 Adds Artificial Intelligence, Machine Learning and Other Enhancements IRVINE, Calif., June 20, 2018 (GLOBE NEWSWIRE) -- Kofax ®, a leading supplier of software to automate and digitally transform information intensive processes, today announced the addition of artificial intelligence (AI), machine learning and other capabilities in its Kapow(TM) 10.3 Robotic Process Automation (RPA) software. Kapow, the #originalbot, automates and digitally transforms a wide range of human and information intensive processes across front and back office operations. It allows users to develop and deploy smart robots that mimic human actions while driving continuous improvement using AI and machine learning. Kapow robots interact seamlessly across desktop software, traditional enterprise and browser based systems and web sites, aggregating data, transforming it into actionable information, triggering responses, and communicating with other applications. Kapow 10.3 leverages AI and machine lear

CNP Assurances: Pre Stabilisation Notice20.6.2018 13:41Pressemelding

PARIS, June 20, 2018 (GLOBE NEWSWIRE) -- EURONEXT PARIS: CNP 20 th June 2018 CNP Assurances Stabilisation Notice HSBC (contact: 'Syndicate desk'; telephone: +44 207 992 8066) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities The securities: Issuer: CNP Assurances Guarantor (if any): Aggregate nominal amount: EUR Bmk Description: EUR Perpetual Fixed Rate Resettable Restricted Tier 1 Notes Offer price: TBC Other offer terms: Stabilisation: Stabilising Manager(s): Credit Suisse / HSBC (B&D) / Morgan Stanley / Natixis / SG CIB / Unicredit Stabilisation period expected to start on: 20th June 2018 Stabilisation period expected to end no later than: 20th July 2018 Existence, maximum size & conditions of use of over-allotment facility: 5% of the aggregate nominal amount Stabilisation Venue(s) Over the counter (OTC) In connection with the offer of the above securities, the Stabilisation Manager(s)

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom